I. A. Kudryavtsev

I. A. Kudryavtsev

Auto-generated profile, based on publicly available information

I. A. Kudryavtsev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
YGYulia Goltseva
Yulia Goltseva
NAN. E. Arnotskaya
N. E. Arnotskaya
IKI. A. Kudryavtsev
I. A. Kudryavtsev
VSV. E. Shevchenko
V. E. Shevchenko
ЮВЮ. Д. Василец
Ю. Д. Василец
The Wnt-signaling pathway regulates various biological processes, such as embryonic development, self-renewal, proliferation, differentiation and migration of stem cells. The Wnt-signaling is involved in tumor progression by aberrant activation in stem-like cells, called cancer stem cells, in different kinds of tumor, including multiform glioblastoma. The Wnt-signaling promotes stemness, invasion, metastasis, therapeutic and immune resistance of cancer stem cells in multiform glioblastoma. To summarize, targeting the Wnt-signaling pathway as an oncogenic driver is the future hope for effective therapy of glioblastoma for which current standard therapy is not effective.In this review, we focused on functions of the Wnt-signaling in cancer stem cells and involvement of the Wnt-signaling pathway in gliomagenesis.

15 January 2021 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
TKT. I. Kushnir
T. I. Kushnir
NAN. E. Arnotskaya
N. E. Arnotskaya
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
ABAli Bekyashev Bekyashev
Ali Bekyashev Bekyashev
VSV. E. Shevchenko
V. E. Shevchenko
Background. Glioblastoma multiforme (GBM) develops in the hypoxic microenvironment, which plays an important role in the pathogenesis of the disease and is closely associated with tumor growth, development and poor prognosis. Hypoxia increases the resistance of tumor cells (TC) to radiation therapy and chemotherapy, promotes the appearance of an aggressive TC phenotype, leading to the disease recurrence. The molecular mechanism of hypoxic action on the secretome of GBM cells, which is involved in the formation of the tumor microenvironment, remains unclear. Also, markers of the aggressive hypoxia-associated phenotype of tumor cells have not been established. The purpose of research – to study the molecular mechanisms of the hypoxia-associated effect on the secretome of the U251 GBM cells.Materials and method. High resolution proteomic mass spectrometry, cell technologies.Results. A total of 1432 proteins were identified in the secretomes of two types of GBM cells (control and experiment). After the action of hypoxia, statistically significant changes in the expression of 390 proteins were registered. 11 proteins showed increase in expression over two orders of magnitude. The intracellular signaling pathways which are responsible for the hypoxia-associated effects on the U251 GMB cells have been identified.Conclusions. Hypoxia significantly affected the proteomic composition of the GBM cells secretome. Five overexpressed secretome proteins, S100A6, HEY1, ZIP3, S100A4, ZEB2, have been proposed as potential markers of the hypoxiaassociated phenotype of GBM, for which participation in the pathogenesis of glioblastoma multiforme has been previously showed.

15 May 2023 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
NAN. E. Arnotskaya
N. E. Arnotskaya
TKT. I. Kushnir
T. I. Kushnir
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
ABAli Bekyashev Bekyashev
Ali Bekyashev Bekyashev
VSV. E. Shevchenko
V. E. Shevchenko
Introduction. Glioblastoma (GB) is not yet curable despite recent advances in the treatment of other malignant solid tumors. The management of GB is based solely on histopathological features, imaging of the tumor and its genomic analysis (somatic mutations in the isocitrate dehydrogenase genes, methylation status of the O6-methylguanine-DNA methyltransferase gene promoter). To adapt the treatment to the most recent tumor evolution, molecular information should be received regularly throughout the course of therapy. However, tumor tissue is often not available for diagnosis as the disease progresses. In this regard, the development of less invasive methods, such as analysis of the proteome of biological fluids of patients, is of particular interest. Cerebrospinal fluid (CSF) is an important source disease biomarkers to monitor the presence and progression of the disease.Aim. To identify proteomic predictive biomarkers in the CSF of patients with GB.Materials and methods. During the study, samples of patients’ CSF samples, high-resolution proteomic mass spectrometry, modern biochemical methods and bioinformatic technologies were used.Results. For the first time, the analysis of proteomes of CSF samples of patients with GB obtained before and 7 days after the removal of the primary tumor was carried out. Potential biomarkers of GB have been identified. After their validation using open databases, 11 proteomic predictive markers of GB (S100A9, S100A8, PLA2G15, PPIB, LTBP2, VIM, LAMB1, STC1, NRP1, COL6A1, HSPA5) were selected and their role in the molecular mechanisms of gliomagenesis was assessed. Conclusion. The proposed panel of proteomic predictive CSF biomarkers in GB patients can be further used in the development of test systems for assessing the effectiveness of therapy and early detection of disease relapses.

15 January 2020 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
TKT. I. Kushnir
T. I. Kushnir
NAN. E. Arnotskaya
N. E. Arnotskaya
IKI. A. Kudryavtsev
I. A. Kudryavtsev
VSV. E. Shevchenko
V. E. Shevchenko
Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patien’s median survival rate ranging from 12 to 15 months. Over the last fifteen years, the treatment for GBM has included maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide chemotherapy. The low efficacy of mentioned therapies has forced researchers to explore an appropriate alternative or complementary treatment for GBM. It has been shown that curcumin has therapeutic potentials to fight against GBM via affecting on cell proliferation, apoptosis, cell cycle, invasion and angiogenesis pathways. In addition, curcumin possess a synergistic impact with chemotherapeutic agents. Herein, we summarized the current findings on curcumin as potential therapeutic agent in the treatment of GBM.

15 September 2022 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VSV. E. Shevchenko
V. E. Shevchenko
ZNZ. N. Nikiforova
Z. N. Nikiforova
TKT. I. Kushnir
T. I. Kushnir
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
NAN. E. Arnotskaya
N. E. Arnotskaya
Introduction. Treatment of glioblastoma multiforme remains little effective due to the rapidly developing recurrence of the tumor, due to its high tumorigenic potential, resistance to chemoradiation therapy and increased dissemination of glioma stem cells. The identification of potential therapeutic targets, which make it possible to more effectively destroy glioma stem cells, becomes topical. In this regard, the study of ferroptosis (FP), which can cause the death of tumor cells with a highly malignant phenotype, is of great importance. However, FP and its regulatory pathways in the GSC are not fully understood. At present, it is also not clear how FP differs for glioma stem cells and glioblastoma differentiated cells.Aim. To study the expression of ferroptosis signaling cascade determinants in CD133+ glioma stem cells and CD133- glioblastoma differentiated cells using high resolution proteomic mass spectrometry.Materials and methods. High-resolution proteomic mass spectrometry, cell technologies.Results. In total, 1970 proteins were identified, 15 of which are associated with ferroptosis and are present in both cell populations. Upregulation of 12 FP determinants (ACSL1, ACSL3, COPZ1, FTH1, FTL, GPX1, GPX4, PCBP1, SLC3A2, TFRC, VDAC1, VDAC2) was found in CD133+ glioblastoma stem cells compared to CD133- differential glioblastoma cells, 10 of which were more than 2-fold overexpressed.Conclusion. Important regularities have been established in the expression of ferroptosis determinants and proteins controlling this process in glioma stem cells, which can be used in the development of new approaches to the detection of potential targets for the therapy of glioblastoma multiforme.

15 December 2021 in Advances in molecular oncology
Verified
Journal Article
Open access
TKT. I. Kushnir
T. I. Kushnir
NAN. E. Arnotskaya
N. E. Arnotskaya
IKI. A. Kudryavtsev
I. A. Kudryavtsev
AMA. A. Mitrofanov
A. A. Mitrofanov
ABAli Bekyashev Bekyashev
Ali Bekyashev Bekyashev
VSV. E. Shevchenko
V. E. Shevchenko
Introduction. To a large extent, the resistance of glioblastoma multiforme to genotoxic therapy is associated with a dysregulation of responses to DNA damage and repair. Thus, suppression of DNA repair mechanisms is a priority pathway for increasing the survival rate of glioblastoma multiforme patients. Curcumin enhances the effectiveness of standard chemotherapy drugs, but its effect on DNA repair systems is not well understood.The study objective – to study the molecular mechanisms of curcumin action on excisional DNA repair in U251 glioblastoma multiforme cells.Materials and methods. high-resolution proteomic mass spectrometry, cell technologies.Results. In the proteomes of two types of glioblastoma multiforme cells (control and experiment), a total of 2757 proteins were identified, of which 39 % were differentially expressed. Significant changes have been found in many signaling cascades that play an important role in carcinogenesis.Conclusion. Curcumin suppressed excisional DNA repair by decreasing the expression of determinants APEX1, MSH6, PARP1. PCNA, POLD1, POLE3, RFC2, RPA.